"An important part of our business strategy has been to realize value from our non-core technologies to fund development of our BPI product platform. This transaction is a good example of the benefits that can come from this approach."
Jack Castello, Chairman, President and CEO, XOMA.
At a Glance
Immunology (rheumatoid arthritis), Oncology (Non-Hodgkin’s lymphoma, leukemia)
Rituxan® (rituximab) was the first monoclonal antibody for cancer approved by the FDA. Launched in late 1997 for the treatment of relapsed or refractory low-grade Non-Hodgkin’s lymphoma, it is used more broadly to treat all types of B-cell lymphoma and all stages of disease, including chronic lymphocytic leukemia. In combination with methotrexate is indicated for the treatment of adult patients with moderately to severely-active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.
Applications In Development:
Immunology (multiple sclerosis, purpura, lupus) and follicular lymphoma